U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07067450) titled 'Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma' on July 04.
Brief Summary: Patients with esophageal cancer still face a high risk of recurrence after receiving neoadjuvant chemoradiotherapy (nCRT) combined with radical surgery, especially for those who do not achieve pathological complete response (non-pCR). Compared with the overall non-pCR population, the subgroup with lymph node positivity has a significantly worse prognosis. The CheckMate 577 study confirmed that in patients with locally advanced resectable esophageal cancer or esophageal-gastric junction cancer, adjuvant treatment with nivolumab after nCRT signif...